Skip to main content
Takanori Ishida on Muck Rack

Takanori Ishida

As seen in: Nature, MDPI, Medscape, The Lancet, Chinese Clinical Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Takanori

Contact Takanori, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Risk factors and metastatic sites in HER2-positive breast cancer with pathological complete response

|
By Hiraku Kumamaru, Naoko Kinukawa, Yasuaki Sagara, Takayuki Iwamoto, Minoru Miyashita, Takanori Ishida, Naruto Taira, Shigehira Saji, Naoki Niikura, Mayako Terao, Toru Hanamura
| Nature Verified
Abstract A pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) is associated with favorable outcomes in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer; however, brain metastases still occur. Using the National Clinical Database–Breast Cancer Registry (JAPAN 2008–2020), we identified 21,494 patients who received NAC followed by surgery.
Open in Who Shared Issue with article?

Clinical Significance of ABCG2/BCRP Quantified by Fluorescent Nanoparticles in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

|
By Hiroshi Tada, Kohsuke Gonda, Narufumi Kitamura, Takanori Ishida
| MDPI
This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessArticle by Hiroshi Tada 1,*, Kohsuke Gonda 2, Narufumi Kitamura 2 and Takanori Ishida 1 1 Division of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Miyagi, Japan 2 Department of Medical Physics, Tohoku University Graduate School of Medicine, Sendai 980-8575, Miyagi, Japan * Author to whom correspondence should be addressed.
Open in Who Shared Issue with article?

Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial

|
By Masakazu Toi, Takanori Ishida, Yoshinori Ito, Shigeru Imoto
| The Lancet Verified
Summary Background Oral fluoropyrimidines, such as S-1, have been shown to have a role in controlling disease progression in metastatic breast cancer. We examined adjuvant treatment with S-1 in patients with oestrogen receptor (ER)-positive and HER2-negative primary breast cancer. Methods We did a multicentre, open-label, randomised, controlled, phase 3 trial in 139 sites (137 hospitals and two clinics).
Open in Who Shared Issue with article?
See all 6 articles